

Page 2 1 HEARING re Notice of Agenda for June 23, 2020 Hearing 2 3 HEARING re Amended Motion of Debtors for Authority to Enter 4 into a Motion for Funding Agreement (related document(s) 5 1005) filed by Marshall Scott Huebner on behalf of Purdue 6 Pharma L.P. (ECF # 1249) 7 HEARING re Notice of Hearing on Application of Stikeman 8 9 Elliott LLP as an Ordinary Course Professional for 10 Compensation for Services Rendered in Excess of the Tier I 11 OCP Cap for the Period from September 15, 2019 through 12 November 30, 2019 [Telephonic] 13 (related document(s)1 126, 548) 14 15 HEARING re Application of the Official Committee of 16 Unsecured Creditors for Entry of an Order Authorizing 17 Retention and Employment of Bedell Cristin Jersey 18 Partnership as Special Foreign Counsel, Nunc Pro Tune to February 27, 2020 filed by Ira S. Dizengoff on behalf of The 19 20 Official Committee of Unsecured Creditors of Purdue Pharma 21 L.P., et al. (ECF #1244) 22 23 24 25 Sonya Ledanski Hyde Transcribed by:

	Page 3
1	APPEARANCES:
2	
3	DAVIS POLK & WARDWELL LLP
4	Attorneys for the Debtor
5	450 Lexington Avenue
6	New York, NY 10017
7	
8	BY: MARSHALL HUEBNER (TELEPHONICALLY)
9	CHRISTOPHER ROBERTSON (TELEPHONICALLY)
10	
11	PILLSBURY WINTHROP SHAW PITTMAN LLP
12	Attorneys for the Ad Hoc Group of Non-Consenting States
13	31 West 52nd Street
14	New York, NY 10019
15	
16	BY: ANDREW TROOP (TELEPHONICALLY)
17	
18	AKIN GUMP STRAUSS HAUER & FELD LLP
19	Attorneys for the Official Committee of Unsecured
20	Creditors
21	One Bryant Park
22	New York, NY 10036
23	
24	BY: ARIK PREIS (TELEPHONICALLY)
25	MITCHELL P. HURLEY (TELEPHONICALLY)

Г	1 9 + 01 +3
	Page 4
1	MILBANK, TWEED, HADLEY & MCCLOY LLP
2	Attorneys for the Raymond Sackler Family
3	28 Liberty Street
4	New York, NY 10005
5	
6	BY: ALEX LEES (TELEPHONICALLY)
7	
8	ALSO PRESENT TELEPHONICALLY:
9	
10	BROOKS BARKER
11	SHEILA BIRNBAUM
12	HAYDEN COLEMAN
13	EDWARD DRUMMOND
14	GEORGE O'CONNOR
15	ALICE TSIER
16	JASMINE BALL
17	JEFFREY ROSEN
18	NATASHA LABOVITZ
19	MAURA MONAGHAN
20	DANIEL E. STROIK
21	HAROLD WILLIFORD
22	CHRISTOPHER ROBERTSON
23	MARC SKAPOF
24	DANIELLE LEVINE
25	KEVIN MACLAY

	Page 5
1	ARTEM SKOROSTENSKY
2	NICHOLAS KAJON
3	CONSTANTINE DEAN POURAKIS
4	GREGORY JOSEPH
5	NICHOLAS PRETY
6	GERARD UZZI
7	KENNETH H. ECKSTEIN
8	CAROLINE GRANGE
9	JEREMY KLEINMAN
10	RAMON NAGUIAT
11	M. VIOLA SO
12	CATRINA SHEA
13	LOWELL FINSON
14	DENNIS CHU
15	JON LOWNE
16	JAMES MCCLAMMY
17	MATTHEW PIERS
18	PAUL SCHWARTZBERG
19	GREGORY KOPACZ
20	EMILY F. MACKAY
21	
22	
23	
24	
25	

PROCEEDINGS

THE COURT: Good morning. This is Judge Drain.

We're here on In re Purdue Pharma, L.P., et al. This is a completely telephonic hearing, so I will ask you to identify yourself and your client the first time you speak. I may do so thereafter if I think the court reporter might not be able to put together your voice with your name.

There's one authorized recording of this hearing or this set of hearings. It's taken by Court Solutions.

Court Solutions provides it to out clerk's office on a daily basis. If you want a transcript, you should contact the clerk's office to arrange for one.

So, with that introduction, I have the amended agenda for today's hearing. And I'm happy to go down the amended agenda.

MR. HUEBNER: Sure. Good morning, Your Honor.

For the record, it's Marshall Huebner of Davis Polk on

behalf of the debtors. Can you hear me clearly?

THE COURT: Oh, yes, fine; thanks.

MR. HUEBNER: Okay; terrific. So this should be a very brief and hopefully positive and excellent hearing.

I'm happy to report that we're starting to build a bit of a track record of uncontested hearings, which is obviously very good progress given that this is a case of great complexity and, obviously, many people for valid reasons

have very strong views on many topics.

The HRT motion as has been substantially amended by the debtors, as Your Honor's no doubt saw in the papers, is really about one thing, which is at this point we're seeking authority to pay \$6.5 million in additional incremental funding to a non-profit pharmaceutical company that as far as we understand, I don't think anybody disagrees, is kind of very much in first place on the progress chart of trying to get over-the-counter naloxone or generic over-the-counter Narcan, one of the most important and (indiscernible) commonly found opioid overdose reversal medications to market.

I'm pretty confident that every single person, entity, and government and practically every stakeholder in this case agrees in concept that having low cost over-the-counter naloxone could potentially be very, very important as a new tool in battling the opioid epidemic. As we lay out in our papers, obviously, OTC naloxone as opposed to prescription, expensive, branded Narcan has the ability to increase access very dramatically and, God willing, save ultimately thousands if not more lives.

We originally filed the motion back on April 7th.

We twice adjourned it. As Your Honor knows, we worked very hard to build consensus wherever possible and avoid contested hearings. Those efforts bore fruit even though

HRT is now just about literally out of money and down to fumes. And we could not adjourn it a third time because they would have actually run out of money, and we told everybody that.

And the good news is that those efforts worked. Ι think as the UCC and others acknowledge, we provided an incredible amount of diligence to multiple parties on many topics: financial, historical, pharmacological, meetings, calls, spreadsheets, and data. We also made a variety of changes to the motion. As Your Honor no doubt saw on the papers, we were originally requesting 11.5 million given that for right now the most important thing is to get through the phase one trial and if the phase one trial succeeds, then hopefully wonderful things will happen and maybe lots of other people will be running in excitement to help fund HRT. And maybe we never even have to move to collect five million because someone else has picked up the slack. Obviously, if the phase one trial goes in a different direction, naloxone may dictate different outcomes.

But just like injectable Nalmafene, which we talked about a couple of hearings ago, and there's another potentially very promising initiative, they're keeping this moving along at a relatively low cost. And I would note -- actually, it's (indiscernible) an hour ago that our most

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

recent reported unrestricted cash balance is \$1.409 billion, which means that this 6.5 million is under one-half of one percent of the debtors' cash. And it's not that every dollar isn't precious because it is, but the question is, you know, is this reasonable in the context of the overall situation.

And so, with genuine thanks and appreciation to many people because some people two months were ready to go to war over this motion, some people were pretty sure they were objecting, some people were moderately sure they were objecting, and I think we listened hard. We made a variety of changes. As Your Honor knows, not only did we cut the relief basically in half, there are, you know, reporting obligations we were happy to agree to because we want the Court to see and be alongside us and either agree that this continuously should develop and is exciting or potentially not. There's certainly nothing to sort of, you know, not be information-sharing — in information-sharing mode about with respect to the key stakeholders.

While I don't think there's any realistic chance, legal or practical, that a non-profit could ever convert to a for-profit company, HRT was instantly and easily happy to agree that if that kind of unthinkable eventuality somehow happened, I actually thing it's probably illegal under state law and I've never heard of such a thing. But, you know,

it's easier to say, sure, we'll put that in than to say that's just totally unneeded. So we put in other provisions that do things like require that they pay back all the money and give us the royalties and all that kind of stuff in case the unthinkable happens and they somehow become for-profit. And, again, the whole vision of this company from inception was to be a non-profit specifically for these purposes.

The Committee filed a pleading and, in part,
because Your Honor is a careful reader. Your Honor has read
a variety of those things in the pleading. I'm going to
touch it very lightly. You know, candidly, there is a lot
in there with which we don't quite agree. There's some
things which we really don't agree. But given that it's not
an objection and the goal is to get through this hearing as
happily and consensually as possible, I'm just going to tap
very lightly five points. I could have picked two, I could
have picked ten. But I just do want the record to be clear
for the Court's benefit since some of these things may
return later in the case where, you know, we don't quite see
it the same way.

We obviously decided not to file a reply because I felt that would have been silly overkill and not a good use of estate money. We're all trying to preserve as best we can. So I'm just going to tap them for two minutes and then sort of end where I began on this point.

One, the statement that OTC and naloxone cannot possibly result in any direct monetary benefit to any creditor in this case and that this is merely a charitable donation, the short answer is we just don't agree with that. And I don't really thing we need to go into why. Over time, you know, OTC and naloxone being developed could actually benefit many creditors in this case, including current creditors, including directly and economically. But, again, it's not up for today, so I just want to note that we see the world a little bit differently.

Two, just I do want to note that I'm going to say it for like the fifth time, we said either two or three times in the motion and many times to people on the phone, this is not a referendum on the form of a plan of reorganization. And this is not a vote, and nobody is silent or support of the motion or lack of objection or filing a statement or not filing a statement should be taken as their consent or support or passion in any direction about what the post-emergence company should be doing with respect to public health initiatives. I think we made that screamingly clear in the amended motion to give everybody comfort on that point.

To be clear, the debtors continue to believe very strongly and are advocating that the post-emergence company should continue and be engaged in doing good and saving

lives and levering its assets in potentially very unique ways that others could not. But today is not that day. The relief, it's very clear and extraordinarily limited, which is \$6.5 million to one non-profit entity.

Three, there is a repeated statement in the UCC filing that sort of no creditors support the PHI or no credit groups support the PHI. I don't want to get into that today. Again, it's just not to the issue. I don't actually think that statement is quite right, and I at least certainly would not be comfortable myself representing what each and every creditor or credit group in this entire case feels or doesn't feel. But, again, it's just not up for today because, as we made clear and one of the main reasons we filed the amended motion in addition to highlighting all the concessions was to sort of say in writing again and again what we told people again and again which is that this motion is not in any way to be seen as viewing, soliciting, accepting, you know, or anything really with respect to the views of other parties than the debtors with respect to the PHI.

Four, the supposition, which I actually think is sort of in bold, maybe even bold and italics, that hundreds of millions of dollars of additional money from Purdue will be needed to bring this product to market, I don't think that's right either. That's one possibility, which is if

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Purdue or Reorganized Purdue -- which certainly will be named something else, I would imagine -- the reorganized debtors were to fund the entire thing and provide X doses for free for Y years, you know, and shoulder every single cost, that certainly could totally hundreds of millions of dollars. I'm sure there are sort of spreadsheets that say that. But there are many possibilities here.

And like with injectable Nalmafene, the goal is to be nimble and flexible and, frankly, many of those decisions will be in the hands of the reorganized company whose decisors will be people appointed by the creditors. So whether they want to sort of do it at cost and sell it at cost and recoup the initial development cost and it doesn't cost anything more or relatively minimal costs, whether they want to sort of have funded the initial cost and then have it be self-sufficient going forward, whether ultimately there are distributor settlements in the opioid larger situation and distributors distribute it for free or help in other ways, those are all chapters that are left to be written and many of those chapters will be written, frankly, after the emergence date when others are presumably in control of these entities.

But, again, it's important that the Court and everyone understand that this is not a foot in the door to a commitment by or on behalf of the debtors that is hundreds

of millions. It may not even be tens of millions. It may not even be millions, depending on sort of which way it goes.

The last topic I just want -- I guess I'll touch on the lightest because, actually, either late last night or this morning, the Ad Hoc Committee did file its own statement on this point, so I'm going to go a little bit lighter, which is the UCC statement sort of thinks out loud about some of its views on public versus private creditors and what each one wants and what each one may logically agree to take it to distribution, and all that stuff.

My only point is I just don't really think that's up for today, and I don't think it's helpful for me to sort of muse back, in part, because there are great many people in this case with a great many views and I have yet to find anyone who is not comfortable articulating their own views when they believe it is necessary and, in part, because I just don't think I should be sort of trying to describe what other people's views are, what they may or may not do under a plan.

But let me end where I started, which is I think a very important and appropriate focus on the positive. Many people came together to think hard about this "economically rather modest but for one reason or another important to them" motion in a constructive way over an extended period.

They asked a lot of questions. They got many answers. Many of them moved off of positions that they felt strongly about. Many members of the UCC, many people who are on the states and other governmental side, many people who felt passionately about the ERF and, like us, are incredibly frustrated that the larger initiatives with, you know, price tags, you know, many, many, many multiples of 6.5 million are not already underway and an initiative that while it has the potential, as many of the papers lay out, to be truly material, is still a couple of year away when we're not doing things that could have impact starting tomorrow. And that's a source of frustration to people.

But all those people, because there's not a single objector out of all the thousands of stakeholders in this case, has decided to object. And so we are grateful for that. We actually hope that it continues to be a harbinger of sort of green chutes and increased productive engagement among many parties who have strong views on many topics.

And with respect to the product itself, you know,

I think we all share the view that, you know, we all hope
that phase one is a redounding success and that this product
takes a leap forward, not just a step forward, in bringing
over-the-counter easily-available very-low-cost naloxone out
to the world, to America but also the rest of the world.
You know, the FDA, as the Court saw in the pleadings, has

done something I was told they've never done before ever for any product, which is they actually did the label themselves so that that could clear a hurdle and wouldn't have to sort of joust with them and get approval. The AMA obviously thinks this is a very important product, as well, with incredible life-saving potential, and we are delighted to bring the uncontested motion to the Court. So let me stop there unless the Court has any questions. It may be that, you know, a couple of other people want to say a few words. I guess I'd also move the declaration of Jon Lowne or the amended declaration of Jon Lowne into evidence so we have the appropriate evidentiary support for the motion formerly sort of accepted into the record, although obviously no one is cross-examining him. There are no objections, but I think just as a matter of housekeeping, that's probably appropriate to do. And that completes my remarks on the first item on the agenda. Thank you. Does anyone want to THE COURT: Okay. question Mr. Lowne on his amended declaration? (No audible response) THE COURT: All right. I have reviewed it, and I will accept it as his direct testimony. (Declaration of Jon Lowne received in evidence) THE COURT: Does anyone else have anything to say

on the motion?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

MR. TROOP: Your Honor, this is Andrew Troop. Just very briefly, and I -- and the non-consenting states do not object to the motion. Last night the Ad Hoc Committee filed a statement and, in light of that, I do feel I need to say something very quickly. As I said, the non-consent states do not object to the motion. We haven't -- we don't affirmatively support it either. And there may be some more discovery that needs to be taken before this path is done further and all those rights are reserved. We appreciate the changes that the debtors made to the motion to make it clear that this is not a referendum on public health initiatives or use in the future. And, in that regard, I just wanted to underscore that the non-consenting states agree with the Ad Hoc Committee's statements in its filing that are consistent with the amended motion. The motion's not a referendum. Public entities' claims include all claims defined in the Bankruptcy Code, past, present, and future claims. And that, you know, from our perspective, we're not sure the UCC was saying anything different, but having joined the issue by the AHC, we just thought it made sense to make it clear on the record where the non-consenting states stand. THE COURT: Okay. MR. TROOP: That's all I have to say, Your Honor.

Thank you.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

THE COURT: Okav.

MR. PREIS: Your Honor, this is Arik Preis from
Akin Gump Strauss Hauer & Feld on behalf of the Committee.
Can I just say probably less than one minute?

THE COURT: Sure.

MR. PREIS: Just as Mr. Huebner pointed out, this is an uncontested motion. We are -- we don't think we need to say anything more than what was in our papers. I would just say two things. One, Mr. Huebner pointed out a few points earlier. I don't think it's necessary for us to respond. Our papers said what they said. Two, as Mr. Troop just pointed out, I don't think we said what the consenting group seems to imply that we said in our papers. But, again, that's not in front of you today, Your Honor, so I -- with that, there's nothing further from us on this matter.

THE COURT: Okay. Anyone else?

(No audible response)

unopposed motion for authorization of the debtors' entry into an amended funding agreement to fund the next two stages or tranches in the development process of either easily-obtained or non-prescription naloxone/Narcon by a not-for-profit entity, HRT. The total funding is -- that is sought to be approved here is 6.5 million. It's part of a process that the debtors began pre-petition as part of their

own not-for-profit efforts to develop and facilitate the development of ways to control or prevent either the abuse or the consequences of taking opioids.

It appears to me that in the context of this case, as articulated in the motion, the continued funding of this project is warranted and it's a proper exercise of the debtor's judgment. The failure to fund the project, in my view, would result in its likely ending. At a minimum, it would result in a substantial suspension of the project.

But, as a practical matter, it would appear to me that the chance of the project proceeding to a result would be unlikely.

So, therefore, in light of that and the due diligence that has been done on the project to confirm that at least as of today, this isn't an investment based on misguided focus on costs but on a belief that the project will in fact bear fruit or at least a reasonable belief that that's the case. This appears to me to be appropriate use of the debtors' funds.

So the debtors can email the order granting the amended motion and approving the amended funding agreement to chambers.

I did read the other pleadings that were submitted in connection with this, and it's clear to me that a substantial amount of time, effort, and money was spent in

connection with analyzing this project. As I've said before in many cases, including this one, the bankruptcy judge sees only about five percent of the case. I don't know and I don't need to know all the work that goes on behind the scenes in connection with motions.

I also don't want to seem to be a scold, but it appears to me that, notwithstanding the large value of these debtors well over a billion dollars, there remains a commonsense principle in all bankruptcy cases where, as is the case here, it would appear to me that the debtors are insolvent. Mainly, people should do only the due diligence that's necessary and approach these matters with a fair measure of common sense. I think, ultimately, that happened here, but given the amount that's being spent, I would hate to think that the cost of analyzing this was even one-tenth of that amount. And I trust that it was far less than that.

I would also note that I hope that the parties are coming to the end of their mediation process as regards to the overall occasion among public claimants on one side and private claimants on the other. I don't want to step on them, but I also want to reiterate what I said last time this needs to move forward promptly.

And I would urge the parties to recognize that there is not a bright line distinction between abatement and satisfying claims. In many, perhaps, most cases, people --

individuals who have been injured by the debtor's product and would have a claim as a result of it would benefit by abatement in one form or another. So my hope is that parties focus on proper due diligence as to reasonable parameters for a program that contemplates abatement, taking into account the interest of individual creditors and their rights but recognizing that many, if not most of them, would benefit from programs that treat and help resolve opioid addiction and that provide resources to various groups to facilitate that.

Again, I don't know where you are in your mediation. I don't want to hear where you are today. But I want to make it clear again that, ultimately, there's a tradeoff between having the best possible plan that parties can imagine and getting it done so the money can get out to people promptly. I agreed reluctantly to defer the roughly \$200-million emergency program in the hope that that would happen promptly, that effort of getting a plan done. It just needs to get done.

So, again, Mr. Huebner, you could submit the order on this motion which obviously, as everyone has said, stands on its own and is not to be taken as any sort of adoption of any other expenditure of the debtors' funds.

MR. HUEBNER: Thank you, Your Honor. We will do so. I would be, by the way, genuinely remiss, although it's

rare I do something like this if I actually did not call out my colleague Christopher Robertson, who I'm about to turn over the podium for the second matter. I mean he really did work almost night and day for months with many stakeholder groups who had, you know, as you said, the Court sees five percent where we (indiscernible) 95 percent. And I think that his stewardship candidly was mission-critical to this motion getting to where it got today, which is uncontested and ready for entry.

So with thanks to Mr. Robertson, let me also turn over the podium to Mr. Robertson. I also did want to note

So with thanks to Mr. Robertson, let me also turn over the podium to Mr. Robertson. I also did want to note that the UCC when we're done with the formal agenda has I think an item or two that they would like to bring up with the Court, and I had told our -- I told Mr. Price last night I would mention that. I realized I had forgot to do it, so that's coming when our three quick agenda items dictates.

So, for now, let me turn the podium over -- the virtual podium to Mr. Robertson.

THE COURT: Okay.

MR. ROBERTSON: Thank you, Marshall, and thank
you, Your Honor. Your Honor, Christopher Robertson, Davis
Polk & Wardwell, on behalf of the debtors. Can you hear me
clearly?

THE COURT: Yes; thanks.

MR. ROBERTSON: Thank you.

The next item on the agenda is the application of Stikeman Elliott, debtors' Canadian counsel, for fees in excess of the Tier 1 OCP cap for the period from September 15th through November 30th. Your Honor, very briefly, the OCP order provides that if the Tier 1 OCPs exceed \$150,000 per month on average over a rolling three-month period, that OCP must file a fee application and seek court approval for the excess amount. Thus far in the case, this is the only such excess fee application. And Stikeman's fees for the three-month period ending November 30th exceeded this cap by an aggregate amount of \$38,999. The fee examiner appointed in these cases has reviewed Stikeman's application and filed his final report yesterday evening at Docket Number 1292. A

As stated in the final report, Stikeman and the fee examiner have agreed to a recommended reduction of \$754 of fees. And Stikeman is, therefore, requesting allowance of compensation in excess of the Tier 1 OCP cap of \$38,245 for the applicable period. And there were no other objections and, as such, this application is unopposed.

I would note, Your Honor, that the fee examiner,
David Clouter (phonetic), is on the phone and available to
address any questions. Otherwise, on behalf of Stikeman, we
would as that Your Honor approve the application subject to
the recommended reduction in the amount of \$38,245. We have
prepared a form of order to submit to chambers if Your Honor

so decides.

THE COURT: Okay. I will grant the application in the revised amount. Let me also note that I do not expect any further filings by the fee examiner unless it's an objection. If I have to amend the order to do that, I'll do it after my earlier remarks about due diligence, costs, and the like. I don't want any more filings on fee applications unless there's an objection by the examiner.

MR. ROBERTSON: Thank you, Your Honor.

THE COURT: And I think the parties understand
why. These are publications. I'm not a big fan of fee
examiners, as a concept. I agreed to one here because it's
a public case. But, again, people have to use common sense.

MR. HUEBNER: And, Your Honor, with that, before the turn the podium over to Akin for the third matter, to the fee examiner's great credit, they actually deserve a shout-out of their own because they have actually gone through every single interim application from the first period, at least to the ones with (indiscernible), caught a bunch of stuff and asked for a reasonable thoughts on appropriate changes. And I think they have actually worked out the entire first four-and-a-half-month period with virtually everybody consensually and quickly. And we hope to submit a revised -- an order as early as later today.

So I do want to give the Court comfort that that

19-23649-shl Doc 1312 Filed 06/24/20 Entered 06/30/20 11:48:25 Main Document Pg 25 of 45 Page 25 1 actually is proceeding with extraordinary speed and 2 efficiency, and there will be I think all in several hundred 3 thousand dollars of reductions because they did catch a bunch of stuff that people agreed to. And so, you know, 4 although it's very strange I guess for a debtors' primary 5 6 counsel to thank or praise the fee examiner who frankly, you 7 know, nobody sort of throws a party when they get one 8 imposed on them or they agree to one. It's actually gone 9 quite efficiently and well so far. So I did want to give --10 THE COURT: Okay. Well, that's good to hear. 11 And, again, I had the holdback in the first interim 12 application because I did want the fee examiner to look at

them. And I'm glad that that's happened promptly and resulted in a consensual order. And that's all I need. I don't need a further report. I trust the examiner's doing his job and if I get a disagreement, then I'll need something. But, otherwise, I won't. So I'm grateful that that's happened as you reported it, Mr. Huebner.

MR. HUEBNER: Perfect. Okay. (Indiscernible) is going very well.

So now let me turn the podium over, I believe, to Ms.

For item number three which is the retention of Jersey counsel by the UCC.

THE COURT: All right.

13

14

15

16

17

18

19

20

21

22

23

24

Page 26 1 MS. BRAUNER: Good morning, Your Honor. 2 Brauner --3 THE COURT: This is the bailiwick of Jersey, not 4 New Jersey. 5 MR. HUEBNER: That is correct. 6 MS. BRAUNER: That is correct, Your Honor. 7 THE COURT: Okay. 8 MR. HUEBNER: This is old -- well, I guess the 9 original Jersey was in England, so this is intermediate Jersey. It's neither old nor new. 10 11 THE COURT: Right. Across the Atlantic Jersey. MS. BRAUNER: Good morning, Your Honor. For the 12 13 record, Sara Brauner, Akin Gump, on behalf of the Official 14 Committee. As Your Honor saw, on June 9th the Committed 15 filed an application to retain Bedell Cristin Jersey 16 Partnership, not New Jersey, at ECF Number 1244 as special 17 foreign counsel to analyze certain issues related to Jersey law, including, among other things, the location and 18 recoverability of certain assets held by members of the 19 20 Sackler family in trust created under the laws of Jersey. 21 As Your Honor certainly saw, no objections were 22 received in respect of the application. In advance of 23 filing the application, the Committee's advisors discussed Bedell's retention with the debtors, and the debtors 24 25 indicated that they would not be objecting. The Committee

also shared the application with the U.S. Trustee in advance of filing and made minor modifications to address certain questions the U.S. Trustee raised.

Edward Drummond, the proposed lead partner on the matter and declarant in respect to the application is on the line to the extent Your Honor has questions about his declaration or otherwise. Absent any questions, we respectfully request that you approve the application in its current form. Thank you, Your Honor.

THE COURT: Okay. I don't have any questions. I noticed that the firm listed its rate in dollars. Is that something the firm normally does with U.S. clients?

MS. BRAUNER: I would defer to Mr. Drummond, but we asked that the firm do so with respect to this matter, and they were happy to oblige.

THE COURT: Okay. All right. Based on the

(indiscernible) in the application, including the

declaration in support, I'll grant the application. So you

can email the order as modified to reflect the comments from
the U.S. Trustee to chambers.

MS. BRAUNER: We will, Your Honor. Thank you.

THE COURT: Okay; thanks.

MR. PREIS: Your Honor, this is Arik Preis from
Akin Gump Strauss Hauer & Feld on behalf of the Creditor's
Committee. That ends the formal part of the agenda. But

we, as Mr. Huebner noted, we have two items that we wanted to address this morning in the way of updates to Your Honor regarding items that were placed on the docket just to keep you apprised of developments in the case. I don't think it's going to take more than five minutes.

May I proceed?

THE COURT: Sure.

MR. PREIS: Okay. The first topic, last night we filed an amended Rule 2019 statement on the docket. As we noted in that filing, we've officially added a third public side ex-officio member to the Official Committee, which is Thornton Township High School District 205 in Illinois, which is a representative public-school district of the group that the parties in the case have been colloquially referring to as the public-school districts.

That group consists of school districts in

Florida, Kentucky, Illinois, and New Mexico and is seeking
to represent a class of approximately 13,000 public school
districts nationwide. The public-school districts assert
claims for damages against the debtors, including the
increased cost of public school, special education, and
supplementary services to children with disabilities due to
prenatal opioid exposure.

The public-school districts assert that their claims are distinct from those of the other public side

creditors. Just as a reminder to you, the public-school districts filed two pleadings in this case over the past three months. First, in early April, they filed a motion to participate in mediation on behalf of the public-school That was ECF Number 998 and 1038. Shortly districts. thereafter, they -- and the parties in interest in the mediation agreed to a stipulation resolving that motion. That was ECF Number 1073 pursuant to which they are now involved in the mediation. Second, in early June, they filed a motion seeking the right to file a class proof of claim. That's ECF Number 1211, which as you know, they voluntarily adjourned to the July omnibus hearing. We are very pleased to add another public side voice to the Creditors Committee, and we just wanted to make you aware of that. THE COURT: Okay. MR. PREIS: The second major topic we would like to address this morning is an update on our investigation of the settlement framework and, specifically, developments regarding discovery. To that, I'm going to cede the podium to my partner, Mitch Hurley, who will speak just on a few things. MR. HURLEY: Thank you, Your Honor. It's Mitch Hurley. Can you hear me?

THE COURT: Yes; good morning.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

MR. HURLEY: Good morning. So, again, Mitch

Hurley with Akin Gump on behalf of the Official Committee of

Unsecured Creditors.

Your Honor, I wanted to provide a very brief update on discovery in the cases, and I think there is some good news to report on that front. First, on June 5th, 2020 at Docket Number 1231, the Official Committee filed with the Court an agreed-upon stipulation among various creditor groups in the case, including the non-consenting state group and numerous private-side creditor groups. The stipulation would provide the Official Committee with the ability to share with its signatories privileged work product and analysis of the Committee and its counsel and professionals. And in exchange and subject to the terms and the stipulation itself, of course, those groups would agree not to seek reimbursement from the estates for undertaking certain kinds of activities.

I understand from my bankruptcy colleagues that this stipulation is at least quite unusual in the exchange of consideration, if you will, that it represents between the creditor groups. And we think it will be very valuable. It followed weeks of negotiation. We think it's going to streamline discovery in the case and save very substantial estate resources.

I also want to note I think it will really enhance

the quality of the ongoing investigation of the claims as it's going to allow an even deeper coordination between the Official Committee's professionals and -- professionals for the many public and private groups who are involved these cases and who have, in some cases, years of experience in facility with the claims arising out of the opioid crisis and other matters of great importance to the cases. So we think that coordination will be valuable in terms of enhancing the quality in investigation and further streamlining the investigation.

The stipulation requires a modification to the protective order in order for it to work. The way the protective order reads now, it forbids a receiving party from sharing protected material with other receiving parties, which obviously would be a problem if the Committee is going to be sharing its work product and analysis with signatories to the stipulation.

We have been negotiating with representatives of the Sacklers a modification to the protective order in an effort to get that change done without requiring court intervention. And we're hopeful that we're going to get there. We aren't there quite yet, but we're hopeful that we will get there. If we don't, of course, we'll have to come back to Your Honor. But we're doing our best to avoid that so that the protective order can be amended on consent.

And then, finally, the ad hoc group of consenting states is not a signatory in the stipulation, as I'm sure Your Honor noticed. The ad hoc group, of course, can speak for itself if they like but, in general, they have asked to negotiate a side agreement with the Committee, the potential terms of which are still under discussion. But it's our hope that we will also soon reach an agreement with the ad hoc group that would allow us to share official Committee work product and analysis with them and their professionals under terms that, as noted, are still being negotiated.

We're going to work hard towards that goal because we think that would also be very effective in help streamlining the process going forward. Unless Your Honor has any questions about the stipulation, I want to turn to a very brief update about where we are in our discovery disputes with the Sacklers.

THE COURT: No, I don't have any questions. I do have a comment, which is that I'm glad that you've proceeded with this. Obviously, people gave some thought to the general concern that had led me to add the reporting and analysis aspect to the discovery orders that I signed. So, as you know, I'm all for streamlining that process given the number of parties involved here. So I'm pleased that the parties on the creditors' side have done that.

MR. HURLEY: Excellent. Thank you, Your Honor.

in the discovery disputes with the Sacklers and the Sacklers' affiliates and wholly-owned companies, including the IACs. Again, there's some good news. The parties have agreed on certain matters related to discovery as embodied in the three stipulations that we filed last night. The stipulations are between the Official Committee and the Mortimer side of the Sackler family, sometimes referred to as Side A and a stipulation between the Committee and the Raymond or Side B Sacklers and a third stipulation between the Committee and the IAC entities that are owned jointly by Side A and Side B and that are referred to by the defined term "stipulating entities" or "stipulating IACs" in the stipulation.

First, I want to thank the Court for helping to break what was an existing log jam. As Your Honor knows, the Committee submitted a letter to the Court on June 2nd and on June 5th received -- the Court received I think six different responses from different law firms representing the Sacklers and their various affiliates. On June 8th, Your Honor, instructed the parties to renew their meet-and-confer efforts, and we believe that instruction coupled with the comments the Court made on the record during the June 3rd hearing really helped propel the parties to an agreement.

Certainly before filing its letter, the Official

Committee had engaged in numerous meet and confers with the stipulating parties and their counsel. And, at least from our perspective, the meet and confers that followed the submission of the letters and Your Honor's comments and instructions were vastly more productive than the ones that preceded those events and have led now to agreements with the Sacklers that we believe represent very substantial progress in terms of creating a schedule for rolling disclosures and privilege logs by Side A and Side B of the Sackler family to be substantially completed in the next few months.

I want to make a quick side note here with respect to a person named Beth Cohen (phonetic). Ms. Cohen is, within the definitions provided in the case stipulation, is a Side B additional-covered Sackler party. But Ms. Cohen is not represented by Milbank. She is represented by the Schulte Law Firm. We believe that the Official Committee will soon have agreement with Ms. Cohen on terms that are substantially similar to those agreed to between the Official Committee and Side B. And we hope to provide that stipulation to the Court promptly. We just aren't there yet, but we think that is very soon to occur.

I want to turn now to the IACs. As the Court is aware, they have new counsel and the IACs are farther behind

in discovery than some of the other parties. So regarding scheduling, the IAC stipulation really describes more of an agreement to agree on a schedule but with a near-term deadline for reaching that agreement or having one imposed by Your Honor, if that becomes necessary, which we of course hope it will not.

I also want to note that as the stipulations in some case expressly contemplate, the Official Committee s soon will move for authorization to serve some additional subpoenas. That's including with respect to the IACs, potentially other entities jointly owned by our affiliate or with the Sacklers as well as Stewart Baker, the Sackler's long-time outside counsel who also had hundreds of executive titles at Purdue and the IACs.

Regarding the IACs, we have made clear to them and their counsel that the Official Committee really feels that it must proceed where possible and appropriate by formal subpoenas. This is in part because, frankly, the Official Committee tried to get discovery from the IACs informally before without success. And without on this call getting into the details the way our request for IAC discovery were handled, any information we were provided about who their counsel was and what that counsel is doing was deeply problematic and troubling.

And, again, I'm not going to get into the details

of that on this call. I don't raise it to point fingers and certainly not at you, counsel for the IACs, which is the Royer Cooper firm. That firm wasn't here and wasn't involved during January and February, March, and April when information was being provided to the Official Committee concerning the IAC's counsel that turned out, for whatever reason, not to be accurate.

I raise the point only to help explain why from the Official Committee's perspective it's practically inconceivable to us that we could proceed at this point with IAC discovery by anything but formal process because of everything that's happened. And that doesn't mean that our work with the IACs isn't going to wait for service of subpoenas. If Your Honor's had a chance to read it, of course, it was -- they were filed late last night, so certainly may not have yet. You'll see that the stipulation expressly provides that we and counsel for the IACs are going to start the meet-and-confer process very promptly. And we have, the Committee has been encouraged by the cooperative approach that Royer Cooper has taken, especially in working over the past couple of weeks towards a stipulation that was filed last night. And we hope, and we do expect, that that's going to continue, that that has been productive -- a productive relationship so far.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

really, we do still intend to seek those formal subpoenas and we will be looking for great expedition from the IACs given the circumstances that led us to where we are now.

And I'm hopeful, and as I said, expect that we can continue to work productively towards that goal with Royer Cooper.

I'll also note that our agreement with the Sacklers calls for the production of privilege logs on a regular basis beginning on July 22nd and after other production deadlines that are contemplated under the stipulations. This is a very important aspect of the agreements from the Committee's perspective. As we anticipate, there may be substantial disagreement among the parties about the viability of privilege claims in the cases, including but not only because, as I alluded to before, certain of the Sacklers (indiscernible) has also held key executive positions at Purdue and the IACs. And since there may be many thorny issues to be resolved, we're very pleased that we now have agreement for production logs to be produced by both sides of the family on a regular basis going forward.

And, with that, Your Honor, that really covers the summary I think of where we are now with the Sackler discovery. I'd yield the phone, though I understand there may be other creditors' side representatives who may wish to speak briefly about discovery. And, of course, if Your

1 Honor has any questions for me, I'd be happy to answer them. 2 THE COURT: Okay. Well, before I hear from anyone 3 else, I am pleased that -- by your report and by the fact that I haven't received any more discovery letters for about 4 5 three weeks. I am not particularly troubled by the issuance 6 of subpoenas. I mean Bankruptcy Rule 2004(c) specifically 7 contemplates it. On the other hand, I am going to remind 8 everyone, although I think the litigators here on all sides 9 are familiar with the bankruptcy process, that this is bankruptcy discovery. It's not in the context of an 10 11 adversary proceeding or contested matter. This is to 12 perform due diligence. It's very important due diligence, 13 but it's to perform due diligence. 14 So those who practice the bankruptcy area should 15 know the difference. And, again the cost/benefit analysis 16 is important, recognizing though, as I've said repeatedly 17 that this is one area in this case where the creditors' side really does need to become comfortable with the facts in 18 19 order to negotiate a plan that would involve the Sacklers. 20 MR. LEES: Your Honor, this is Alex Lee at 21 Milbank. May I be heard briefly? 22 THE COURT: Sure. I was going to say I don't know if anyone else has anything more to say on this, but you're 23 24 free to if you want to. 25 MR. LEES: Thank you, Your Honor. Alex Lees of

Milbank for the Raymond Sackler family. Mr. Hurley said quite a bit in his presentation, and I don't think it would be productive or useful to try to get into a tit-for-tat about everything.

But one particular comment that I did not want to leave hanging out there was his suggestion that somehow, we or our clients were not being cooperative in discovery until the Official Committee filed its letter a few weeks ago. We view that as not an accurate presentation of the facts. We believe that the meet-and-confer process was working and that we were being cooperative and offering compromises, albeit in the context of bona fide disputes which happened here. And we don't think that the letter served as a catalyst for any level of cooperation that wasn't already there. And I didn't want --

THE COURT: Okay.

MR. LEES: -- our silence on the issue to be taken as suggesting our acquiescence in the presentation of the facts. That's all, Your Honor.

THE COURT: That's fine. I'm not sure what the facts of discovery really matter anyway. The ultimate result is what counts, so -- but thank you.

MS. BALL: Your Honor, apologies; this is Jasmine Ball from Debevoise & Plimpton for the Mortimer side. I'm just going to echo what Mr. Lees just said just for the

record for purposes --

THE COURT: Okay. Thank you.

MS. BALL: Thank you.

MR. HUEBNER: Your Honor, this is Marshall Huebner for a minute from the debtors' perspective, I should note I think we are something like nine months and eight days into the case. I think that, you know, Your Honor actually made other comments before that I think relate to everything that we all are doing. You know, there is obviously a balance to be struck between a run rate that is now growing rather torrid on discovery issues with very, very legitimate needs of the creditor body ideally through efficient processes that many of us have authored and championed and co-authored to get it done the right way.

I should also note that I think that if anybody sort of had taken bets on the opening day of the case whether nine months later there would be note be a single discovery requesting having been filed against the debtors, I don't think anybody would have taken that side of the bet. And I do want to sort of give a shout out to many people for the fact that with respect to the debtors, the UCC and the debtors and many other parties have worked out I think almost literally all or virtually all sort of information requests. We're very close to I think agreement on the smaller many issues. Those are obviously largely handled by

others and really not very much at all by me, but it is a tremendous, tremendous work stream.

I see, you know, dozens of emails a week with this custodian and this and search terms and parameters and hits and de-duping and re-duping, and QC. And, again, the Court should know just for a glimmer since I don't give sort of full State of the Union reports to the Court, but when the topic does come up that there's just a massive amount of work that has gone on in good faith by many parties. And while there may be subpoenas and 2004 (indiscernible)

Sacklers, I didn't want to leave it entirely unmentioned that there has been not one against Purdue and that's for very good reason, which is a tremendously cooperative and also intense and also expensive and the like process.

So I did want to just quickly note that. Your Honor, we have no other items before --

MR. TROOP: Actually, Mr. Huebner, before you wrap up, if I may?

MR. HUEBNER: Sure.

MR. TROOP: Thank you.

Your Honor, this is Andrew Troop and the nonconsenting state group. I didn't think that Mr. Huebner was
going to go where he did. But, again, in an effort of full
transparency with the Court and with the parties, first off,
we are fully committed to working to enhance the quality of

the investigation and be efficient with the UCC. And, in that regard, we have with the UCC engaged in substantial what I'm going to call non-compulsory discovery requests with the debtors.

And I am hopeful, like Mr. Huebner is hopeful,
that with the couple of open issues that remain, those -with the debtors, those will be resolved soon this week.
But as a heads up, I think that with the support of the
Committee, the Creditor's Committee, if we can't resolve
those issues this week, we may need to bring those remaining
few meaningful categories of disagreement before you.

I am very hopeful that is not where we will end up, but the open requests are ones that really go to the heart of the issues that you've described as being on the creditors' plate for confirmation understanding. And we'll need to get to the bottom of that, as well, given everyone's effort I think to try to move this case as long as quickly as possible. We're probably getting to the point where we can't delay talking with you about the issue, the issues if we can't resolve them this week.

So just so that you know, Your Honor, that's out there.

THE COURT: Okay.

MR. TROOP: And --

25 THE COURT: I'm hopeful, too, that you won't need

Page 43 1 But if you do, you know, you can schedule a call. But 2 I'm hopeful you'll be able to work them out as you worked 3 out the others ones with (indiscernible). 4 MR. TROOP: Yes, Your Honor. Thank you. 5 THE COURT: Okay. All right. 6 Mr. Huebner, I think you were about to say we're 7 done? MR. HUEBNER: Yeah. No, so we ended up 97 percent 8 9 joy, 3 percent buzz stop, but I think we are now definitely 10 done. 11 THE COURT: All right. Very well. I'm going to 12 ring off then. There are no other matters on this morning's 13 calendar, so thank you all. 14 Thank you, Your Honor. COUNSEL: 15 THE COURT: Bye bye. 16 (Whereupon these proceedings were concluded) 17 18 19 20 21 22 23 24 25

	Py 44 01 45		
			Page 44
1	INDEX		
2			
3	RULINGS		
4		Page	Line
5	Amended Motion of Debtors for Authority	18	18
6	to Enter into a Motion for Funding		
7	Agreement - Granted		
8			
9	Application of Stikeman Elliott, LLP,	24	2
10	As an Ordinary Course Professional for		
11	Compensation of Services Rendered in		
12	Excess of the Tier 1 OCP Cap for the		
13	Period from September 15, 2019 through		
14	November 30, 2019 - Granted		
15			
16	Application of the Official Committee of	27	18
17	Unsecured Creditors for Entry of an Order		
18	Authorizing Retention and Employment of		
19	Bedell Cristin Jersey Partnership as		
20	Special Foreign Counsel, Nunc Pro Tunc		
21			
22			
23			
24			
25			

Page 45 1 CERTIFICATION 2 3 I, Sonya Ledanski Hyde, certified that the foregoing 4 transcript is a true and accurate record of the proceedings. 5 anya M. deolarahi Hyd 6 7 8 Sonya Ledanski Hyde 9 10 11 12 13 14 15 16 17 18 19 20 Veritext Legal Solutions 21 330 Old Country Road 22 Suite 300 23 Mineola, NY 11501 24 25 Date: June 24, 2020